Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Status:
Completed
Trial end date:
2017-03-03
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if dasatinib can help to control
myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.